Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma
Status:
Withdrawn
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effects, good and bad, of gamma secretase inhibitor
PF-03084014 and to see how well it works in treating patients with acquired immune deficiency
virus (AIDS)-associated Kaposi sarcoma. Gamma secretase inhibitor PF-03084014 may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth and may shrink
the tumor.
Phase:
Phase 2
Details
Lead Sponsor:
AIDS Malignancy Consortium
Collaborators:
National Cancer Institute (NCI) The Emmes Company, LLC The EMMES Corporation